Vous avez cherché: international metastatic rcc database conso... (Anglais - Maltais)

the phase 2 portion enrolled a total of 153 patients with unresectable advanced or metastatic rcc following 1 prior vegf-targeted treatment.
il-porzjon ta’ fażi 2 irreġistra total ta’ 153 pazjent b’rcc avvanzat jew metastatiku li ma jistax jitneħħa b’operazzjoni wara kura waħda fil-passat b’vegf immirat.

patients (n = 435) with locally advanced and/or metastatic rcc were randomised to receive pazopanib 800 mg once daily or placebo.
pazjenti (n = 435) b’rcc lokali avvanzat u/jew metastatiku ġew randomizzati sabiex jirċievu jew 800 mg pazopanib darba kuljum jew plaċebo.

a multicenter, randomised, open-label, trial was conducted to determine the safety and efficacy of lenvatinib administered alone or in combination with everolimus in subjects with unresectable advanced or metastatic rcc.
twettqet prova multiċentrika, li fiha l-parteċipanti ntgħażlu b’mod każwali, open-label, biex tistabbilixxi s-sigurtà u l-effikaċja ta’ lenvatinib mogħti waħdu jew flimkien ma’ everolimus f’individwi b’rcc avvanzat jew metastatiku, li ma jistax jitneħħa b’operazzjoni.

treatment-naïve metastatic renal cell carcinoma (mrcc) a phase 3 randomized, multicenter, international, study evaluating the efficacy and safety of sunitinib compared with ifn-α in patients with treatment-naïve metastatic rcc was conducted.
trattament li qatt ma kien ittieħed qabel għal- karċinoma metastatika taċ- Ċellola renali (mrcc) studju fażi 3 randomizzat, f’ ċentri multipli, internazzjonali kien magħmul biex jevalwa l- effikaċja u s - sigurtà ta ’ sunitinib f’ pazjenti fuq ifn- α imqabbel ma ’ trattament mrcc li qatt ma kien ittieħed qabel.

in veg108844, patients (n = 1110) with locally advanced and/or metastatic rcc who had not received prior systemic therapy, were randomised to receive either pazopanib 800 mg once daily continuously or sunitinib 50 mg once daily in 6-week cycles of dosing with 4 weeks on treatment followed by 2 weeks without treatment.
f’veg108844, pazjenti (n = 1110) b’rcc avvanzata lokalment u/jew metastatika li ma kinux irċevew terapija sistemika qabel, kienu randomized biex jirċievu pazopanib 800 mg darba kuljum kontinwament jew sunitinib 50 mg darba kuljum f’ċikli ta’ dożaġg ta’ 6 ġimgħat b’4 ġimgħat fuq kura segwit b’ġimagħtejn mingħajr kura.